2-氯-4-氟苯肼盐酸盐 | 497959-29-2

• 物质功能分类: 化学试剂 - 有机试剂 - 肼
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-4-氟苯肼盐酸盐
• 中文别名: 2-氯-4-氟苯肼；2-氯-4-氟苯肼HC
• 英文名称: (2-chloro-4-fluorophenyl)hydrazine hydrochloride
• 英文别名: 2-Chloro-4-fluorophenylhydrazine hydrochloride；(2-chloro-4-fluorophenyl)hydrazine;hydrochloride
• CAS: 497959-29-2
• 化学式: C₆H₆ClFN₂*ClH
• 分子量: 197.039
• InChiKey: QELCWIMDZKOJBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.95
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  29280000
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-4-fluorophenylhydrazine, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-4-fluorophenylhydrazine, HCl
CAS number: 497959-29-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6ClFN2.ClH
Molecular weight: 197

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-4-氟苯肼盐酸盐 在 盐酸 、 水 、 溶剂黄146 、 cesium fluoride 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 14.33h， 生成 8-chloro-6-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-ol
  参考文献：
  名称：

  [EN] SELECTIVE ANDROGEN RECEPTOR MODULATORS
  [FR] MODULATEURS SÉLECTIFS DU RÉCEPTEUR DES ANDROGÈNES

  摘要：

  该发明提供了化合物的公式（I）、（Ia）、（Ib）、（Ic）、（II）、（IIa）或（III）及其盐，包含化合物的制药组合物的公式（I）、（Ia）、（Ib）、（Ic）、（II）、（IIa）或（III）和药用可接受的赋形剂，调节雄激素受体的方法，治疗通过雄激素受体调节剂有益治疗的疾病的方法（例如，肌少症、前列腺癌、避孕、与2型糖尿病相关的紊乱或疾病、贫血、抑郁症和肾脏疾病），以及制备化合物的公式（I）、（Ia）、（Ib）、（Ic）、（II）、（IIa）或（III）和在其制备中有用的中间体的工艺。

  公开号：

  WO2011097496A1
• 作为产物：
  描述：

  2-氯-4-氟苯胺 在 盐酸 、 sodium nitrite 、 tin(ll) chloride 作用下， 以 水 为溶剂， 生成 2-氯-4-氟苯肼盐酸盐
  参考文献：
  名称：

  作为琥珀酸脱氢酶抑制剂的新型氨基环丁烷甲酸衍生物的发现

  摘要：

  构象限制开关概念已被采用作为药物结构优化的主要工具，以扩大化学结构范围并提高针对特定蛋白质的治疗活性。与阳性对照啶酰菌胺相比，以此方式生产的几种1-氨基环丁烷甲酸衍生物在体外表现出令人满意的抗真菌活性。体外抗真菌试验表明，化合物A21对立枯丝核菌( R.s.，EC 50 = 0.03 mg/L)和灰葡萄孢( B.c.，EC 50 = 0.04 mg/L)具有相当甚至更高的抗真菌活性。Fluxapyroxad（R.s.，EC 50 = 0.02 mg/L；B.c.，EC 50 = 0.20 mg/L）和啶酰菌胺（R.s. ， EC 50 = 0.29 mg/ L；B.c.，EC ）50 = 0.42 毫克/升）。此外，成功筛选到的化合物A20对猪SDH具有良好的抑制活性，其IC 50值为3.73 μM，与fluxapyroxad（IC 50 = 3.76 μM）相比具有相当的药效。使用 SEM

  DOI：

  10.1021/acs.jafc.3c01429

文献信息

• [EN] AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES<br/>[FR] DÉRIVÉS DE CYCLOHEXANE À SUBSTITUTION AMIDO
  申请人：BAYER PHARMA AG

  公开号：WO2018078009A1

  公开（公告）日：2018-05-03

  The present invention relates to amido-substituted cyclohexane compounds of general formula (I) : in which m, A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式(I)的酰胺取代的环己烷化合物，其中m、A、R4、R6、R7、R8、R9、R10和R11如本文所定义，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是肿瘤，作为唯一药剂或与其他活性成分结合使用。
• Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase
  申请人：Banner Lester Bruce

  公开号：US20070049632A1

  公开（公告）日：2007-03-01

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式(I)的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
• [EN] SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE TRIAZOLE SUBSTITUÉS ET UTILISATIONS ASSOCIÉES
  申请人：BAYER PHARMA AG

  公开号：WO2019081302A1

  公开（公告）日：2019-05-02

  The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

  本发明涉及新型的取代1,2,4-三唑衍生物，这些化合物的制备方法，包含这些化合物的药物组合物，以及这些化合物或组合物用于治疗和/或预防疾病的使用，特别用于治疗和/或预防肾脏和心血管疾病。
• Chemical and Biological Investigation of Cyclopropyl Containing Diaryl-pyrazole-3-carboxamides as Novel and Potent Cannabinoid Type 1 Receptor Antagonists
  作者：György Szabó、Balázs Varga、Dóra Páyer-Lengyel、Attila Szemző、Péter Erdélyi、Krisztina Vukics、Judit Szikra、Éva Hegyi、Mónika Vastag、Béla Kiss、Judit Laszy、István Gyertyán、János Fischer

  DOI：10.1021/jm900179y

  日期：2009.7.23

  in the search for effective therapeutic agents. One of these, antagonism of the cannabinoid 1 (CB1) receptor, rose to prominence following reports demonstrating the positive modulation of food intake by the CB1 antagonist, rimonabant (3) (SR141716A). In the present study, various diaryl-pyrazole derivatives containing cycloalkyl building blocks were synthesized and tested for CB1 receptor binding affinities

  肥胖是西方世界的主要临床问题，在寻找有效的治疗剂中已经探索了许多分子靶标。其中之一是对大麻素1（CB1）受体的拮抗作用，在有报道表明CB1拮抗剂利莫那班（3）（SR141716A）对食物摄入有积极调节作用后，这种作用日益突出。在本研究中，合成了各种含有环烷基结构单元的二芳基-吡唑衍生物，并测试了其与CB1受体的结合亲和力。彻底的结构-活性关系（SAR）研究优化了吡唑取代基，导致了几种新型的K i CB1拮抗剂≤5 nM，并且与人肝微粒体具有可接受的代谢稳定性。在这些类似物中，我们鉴定出5-（4-环丙基苯基）-1-（2,4-二氯苯基）-4-乙基-N-吡咯烷-1-基-1H-吡唑-3-羧酰胺（11r），它们具有与临床参考文献相比，具有良好的药理作用，在降低代谢综合征的血脂参数方面具有出色的功效。
• Synthesis and biological evaluation of panaxatriol derivatives against myocardial ischemia/reperfusion injury in the rat
  作者：Qiong Wu、Ruiying Wang、Yang Shi、Wenchao Li、Meng Li、Peng Chen、Bowen Pan、Qing Wang、Caifeng Li、Jianbing Wang、Guibo Sun、Xiaobo Sun、Hongzheng Fu

  DOI：10.1016/j.ejmech.2019.111729

  日期：2020.1

  Panaxatriol (PT) is a natural product derived from ginseng that possesses cardioprotective effects in isolated rat hearts. To develop more potent therapeutic agents against myocardial ischemia/reperfusion (MI/R) injury from natural products, a novel series of heterocycle ring-fused panaxatriol derivatives were designed and synthesized. In vitro results showed that approximately half of them exhibited

  人参三醇（PT）是人参的天然产物，在离体大鼠心脏中具有心脏保护作用。为了开发更有效的天然产物对心肌缺血/再灌注（MI / R）损伤的治疗剂，设计并合成了一系列新的杂环稠环人参三醇衍生物。体外结果表明，在氧-葡萄糖剥夺和再灌注（OGD / R）损伤的心肌细胞模型中，与PT相比，它们中约有一半具有更高的细胞保护活性。此外，还在MI / R损伤的大鼠模型中证实了代表性衍生物化合物18的体外活性。体内结果显示18可以明显减少大鼠心肌梗死面积，减少循环心肌肌钙蛋白I（cTnI）泄漏并减轻大鼠心脏组织损伤。